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Background: The physiology and pharmacology of activation or perception of activation of pain-coding
trigeminovascular afferents in humans is fundamental to understanding the biology of headache and developing new
treatments.
Methods: The blink reflex was elicited using a concentric electrode and recorded in four separate sessions, at baseline
and two minutes after administration of ramped doses of diazepam (final dose 0.07 mg/kg), fentanyl (final dose
1.11 μg/kg), ketamine (final dose 0.084 mg/kg) and 0.9 % saline solution. The AUC (area under the curve, μV*ms) and
the latency (ms) of the ipsi- and contralateral R2 component of the blink reflex were calculated by PC-based offline
analysis. Immediately after each block of blink reflex recordings certain psychometric parameters were assessed.
Results: There was an effect due to DRUG on the ipsilateral (F3,60 = 7.3, P < 0.001) AUC as well as on the contralateral
(F3,60 = 6.02, P < 0.001) AUC across the study.
A significant decrement in comparison to placebo was observed only for diazepam, affecting the ipsilateral AUC. The
scores of alertness, calmness, contentedness, reaction time and precision were not affected by the DRUG across
the sessions.
Conclusion: Previous studies suggest central, rather than peripheral changes in nociceptive trigeminal transmission in
migraine. This study demonstrates a robust effect of benzodiazepine receptor modulation of the nociception specific
blink reflex (nBR) without any μ-opiate or glutamate NMDA receptor component. The nociception specific blink reflex
offers a reproducible, quantifiable method of assessment of trigeminal nociceptive system in humans that can be used
to dissect pharmacology relevant to primary headache disorders.
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The physiology and pharmacology of head pain underpins
understanding of the various syndromes and development
of new therapies for conditions such as migraine and clus-
ter headache. Migraine is an episodic brain disorder that
affects about 15–18 % of the population [1], is the most
common cause of disability due to a neurological disorder
[2] and has been estimated to be the most costly neuro-
logical disorder in the European Community at more than
€27 billion per year [3]. Major therapeutic development,
in the form of relatively specific and effective acute [4, 5]* Correspondence: peter.goadsby@kcl.ac.uk
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the Creative Commons license, and indicate ifand preventive [6, 7] treatments of migraine have provided
impetus to understand their mechanism of action. Since
activation, or the perception of activation, of pain-coding
trigeminovascular afferents underlies most disabling pri-
mary headaches [8], understanding human trigeminal
mechanisms is essential for therapeutic development. The
description of a method for activating the trigeminal sys-
tem in humans to study pain-induced responses [9] has
spurred many studies of this crucial pathway [10].
The blink reflex (BR) is a physiological, protective
trigeminofacial reflex aimed at facilitating eyelid closure
as a response to a threatening and potentially harmful
stimulus [11]. In clinical practice the BR can be elicited
when the skin innervated by the supraorbital nerve is
electrically stimulated and a compound muscle action
potential (CMAP) from the surface of the orbicularisdistributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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supplied by branches of the trigeminal nerve, and the
efferent volleys are conducted by branches of the facial
nerve. Suprasegmental influences on the BR are less well
understood, but evidence from studies in patients with
movement disorders, stroke and multiple sclerosis sug-
gest input from the central cortex, basal ganglia and
thalamus [12]. The reflex response consists of three com-
ponents – R1, R2, and R3. R1 is mediated by exteroceptive
A-beta fibers that project to low-threshold mechanorecep-
tive neurons in the pons [11, 13]. This response has an ipsi-
lateral oligosynaptic reflex arc connecting the Gasserian
ganglion to the pontine sensory nucleus of the trigeminal
nerve and subsequently to the ipsilateral facial nucleus [14].
The R2 response is mediated by A-beta and A-delta fibers,
projecting to wide dynamic range (WDR) neurons in the
medulla including this of the spinal trigeminal nucleus [15].
R3 is mediated by A-beta and A-delta fibers and the precise
connections are debated [16]. R3 and R2 are bilateral
responses elicited by both noxious and innocuous stimuli.
Only R2 can be elicited by selective activation of noci-
ceptors [17]. Kaube and colleagues [9] developed a
novel concentric electrode to allow specific study of
nociceptive components of the R2 component of the
reflex, the nociception-specific blink reflex (nBR).
It has been reported that fentanyl, an opioid receptor
agonist, and diazepam both reduce the R2 component of
the blink reflex [18]. Ketamine, despite its use in pain [19],
has only infrequently been studied in migraine [9, 20], and
most recently in migraine aura [21]. In this study we sought
to explore the pharmacology of the nociceptive portion of
the R2 response using the novel concentric electrode, and
thus provide data in humans on some aspects of the
pharmacology of this important synapse.
Methods
Demographics
The study was approved by The National Hospital for
Neurology and Neurosurgery and The Institute of
Neurology Joint Research Ethics Committee and
Directorate for Research and Development. Male vol-
unteers (n = 31) aged between 21 and 37 years under-
went initial screening assessment, which included a
careful history and physical examination, after signing
an informed consent document that explained and de-
scribed the study. Ten subjects were unsuitable because
of intercurrent medical issues (n = 6) or for practical (n = 4)
reasons, the latter being that they could not agree to attend
on repeated occasions. Twenty-one non-smoking [22]
subjects 27 ± 4 years old (mean ± SD) with unremark-
able medical history, including no history of a headache
disorder, normal physical examination and clinical la-
boratory tests, including negative urine drug screening,
were recruited into the study. None of the volunteersreceived any prescribed medication for 30 days prior to
the screening or after entering the study, for its entire
duration. No medication was used during the 24 h prior
to the recordings. Alcohol consumption was restricted
to less than 10 units per week, with no intake for 24 h
prior to and after each recording.Recordings
All recordings were carried out between 9.00 and 17.30,
with at least one common to all investigator blinded to
the treatment (JCAM), under similar conditions and
using the same verbal instructions on each occasion.
The subjects were lying supine, in a comfortable adjust-
able bed in a warm room with dim light, keeping their
eyes closed during the recordings. When required, gen-
tle pressure was applied on the eye lids by an eye pad,
helping the subjects to relax, in order to avoid interfer-
ence by eyelid fluttering and thus reduce noise. EMG
recordings were obtained from bilateral gold-plated
surface electrodes placed infraorbitally over the belly of
the orbicularis oculi muscle (different) and the lateral
orbital ridge (indifferent); acquisition band width 1 to
1000 Hz (in isolated cases the lower cut off frequency
was increased from 1 to 20 Hz to avoid clipping of the
signal due to pronounced EOG responses), sampling
rate 2.5 kHz (750 data points/sweep), sweep length
300 ms, amplifier gain 10,000 X (micro 1401, Signal
Version 2, Cambridge Electronic Design, UK).Stimulation
Blink reflexes were elicited with a custom built concen-
tric electrode in using a printed circuit board design:
central platinum cathode (D: 0.5 mm) and an external
anode ring (D: 6 mm; thickness 1 mm), providing a
stimulation area of 20 mm2, placed about 10 mm above
the right supraorbital foramen [9]. Stimulation was per-
formed with a constant current source (Stimulator
DS7A Digitimer, UK) by delivering a train of three
square wave monopolar (positive) pulses [23], each last-
ing 0.5 ms, with an interpulse interval of 4 ms, max-
imum voltage 400 V. The current intensity for
nociception-specific stimulation was 0.5–1.8 mA (mean
0.95 ± 0.19 mA), representing 2–4 times individual
threshold for pin-prick perception (mean 0.31 ±
0.06 mA) [24]. Each session (of a total of four) consisted
of four blocks (one at the base line and one after each
dose, see below), separated by 10 min. Each block con-
sisted of seven sweeps with an inter-stimulus interval of
12–18 s (randomized, uniform distribution). Grounding
to earth was secured by a moist wrist band electrode or
by a standard disposable ECG gel electrode placed
over the mastoid protuberance.
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In a single-center, randomized, double-blinded, placebo-
controlled, crossover, four-arm study, the sensitivity of
the blink reflex, as a marker of the central activity of
diazepam, fentanyl and ketamine, was assessed versus
specific CNS related parameters.
The volunteers were randomly assigned to receive a se-
quence of four treatments each, on four different occasions,
separated by a washout period of a minimum four days.
Treatments
The subjects were cannulated and received either a ramped
dose of intravenous diazepam: initial dose 0.03 mg/kg with
two subsequent increments of 0.02 mg/kg each [25]; intra-
venous fentanyl: initial dose 0.37 μg/kg with two additional
increments of 0.37 μg/kg each [26, 27]; intravenous keta-
mine: initial dose 0.028 mg/kg with two subsequent identi-
cal increments of 0.028 mg/kg [28–30], or intravenous
placebo. Placebo was given as pure saline infusion and the
active drugs were mixed with saline solution, all adminis-
trated from a 50 ml volume syringe. Each infusion (dose
increment), including placebo increments, was delivered
over two minutes (300 ml/h) using an IVAC (TIVA
ALARIS Medical Systems, Hampshire, UK) infusion pump.
Data collection
Continuous telemetric ECG, pulse, oxygen saturation
and respiratory rate monitoring and intermittent (every
10 min) blood pressure measurements were performed
during and two hours following the experiments (Philips
C3 Patient Monitor 862474, USA). During every session,
assessments of the blink reflex (see Statistical analysis)
took place at the base line and two minutes after each
dose increment, respectively.
Psychometric tests
Immediately after each block of blink reflex recordings
certain psychometric parameters were objectively assessed
by measuring the speed of reaction and the accuracy of
responses to visual stimuli (as described below) and sub-
jectively, using a computer adapted (Matlab 5.3, The
MathWorks, Nattick, MA, US) version of Bond Lader
Rating Scale [31]. The test consisted of 16 pairs of oppos-
ite adjectives, each pair presented separately, with the
opposite words delineating a 155 mm long and 20 mm
wide bar, horizontally centred on a 15 in. Dell computer
screen, positioned at a comfortable distance and in an
appropriate visual angle. The subjects were instructed to
mark the extent to which they felt the two opposite adjec-
tives corresponded to their state of mind (i.e. closer to one
quality and more distanced from its opposite) using a
cross-hair cursor controlled by a mouse. The distance in
mm was measured, the scores reversed and then analyseswere made on three different fields, measuring alertness,
calmness and contentedness.
To monitor objectively the subjects’ level of alertness a
special function was edited in Matlab using Cogent 2000
(version 1.24) to present fifty pairs of either identical or
almost identical (four identical digits, one different) five
digit figures (Arial size 100), on the same computer
screen described above. Each figure was presented for
200 ms with an inter-figure interval of 400 ms. The
subjects were instructed to hit a key (arbitrarily chosen
on a keyboard) when the paired figures were identical
and a different key when the paired figures were not
identical, as soon as possible, after the second figure in
each pair was presented. The same keys being used for
identical respective different events through the entire
test. The reaction time was monitored up to 1000 ms
after the presentation of the second figure in each pair.
Slower responses were computerized as errors and
excluded from the averaged reaction time in a final (after
each test) score of error rate and mean reaction time.
The subjects were allowed to familiarize with both tests
(reaction performance and Bond Lader Rating Scale)
before the first experiment.Data analysis
The first recording sweep on all recordings was discarded
to avoid contamination by initial startle responses. The
onset latency (ms) and the area under the curve AUC (μV
x ms) of the R2 component (rectified EMG) between 35
and 95 ms were calculated by PC-based offline analysis
with custom written software programmed in Matlab.
Data were recorded on an Excel spreadsheet and checked
before the database was locked and the randomisation
code was broken. Summary data are presented as mean ±
SEM. Reproducibility between visits was tested with Cron-
bach’s alpha. Data were analysed initially using an
ANOVA with repeated measures for an effect of TIME
and DRUG treating each study episode as independent.
To examine the three independent hypotheses regarding
opioid, benzodiazepine and glutamatergic involvement in
the nociception-specific blink reflex the ANOVA with
repeated measures regarded treatment episodes as related
within subjects and examined the DRUG main effect with
Bonferroni correction (SPSS for Windows). If Mauchly’s
test of sphericity was violated, we made appropriate cor-
rections to degrees of freedom according to Greenhouse–
Geisser. Significance was assessed at the P < 0.05 level.Results
All subjects completed the entire cross-over with no
drop-outs. The volunteers had a mass of 72 ± 8 kg and
were 1.8 ± 0.1 m in height.
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Baseline blood pressure (mean arterial pressure, MAP =
2/3* Diastolic + 1/3 *Systolic) was 87 ± 2 mmHg, heart
rate 62 ± 2 beats/min, respiratory rate was 20 ± 1 breaths
per minute and oxygen saturation 98 ± 1 %.Blink reflex
The baseline ipsilateral AUCs (μV.ms) for the four visits
(ketamine, diazepam, fentanyl and placebo) were (mean ±
SEM): 2082 ± 283, 1892 ± 299, 2340 ± 376 and 2011 ± 341,
respectively. These were highly reproducible (alpha = 0.85,
Fig. 1a). The baseline ipsilateral latencies (ms) for the four
visits were: 41.8 ± 1.5, 43.5 ± 2.3, 42.9 ± 1.9 and 45.1 ± 2.3,
respectively. Again these were highly reproducible (alpha
= 0.86, Fig. 1b). The baseline contralateral AUCs (μV.ms)
for the four visits were: 1364 ± 239, 1156 ± 188, 1461 ±
324 and 1336 ± 306, respectively. The baseline contralat-
eral latencies (ms) for the four visits were 47 ± 2, 47 ± 3,
46 ± 3 and 46 ± 3, respectively.Fig. 1 Baseline measures of the nociception specific blink reflex from
twenty-one volunteers on four separate visits showing a high degree of
reproducibility of intra-patient measures for the area-under-the-curve
(AUC, μV.ms, Panel a) and latency (ms, b) for the ipsilateral responses.
Contralateral responses were similarly reproducible (see Results)Neuropsychological tests
From the Bond-Lader scale the alertness (ketamine 30 ± 4,
diazepam 23 ± 3, fentanyl 25 ± 3 and placebo 25 ± 4),
calmness (28 ± 4, 24 ± 4, 27 ± 4 and 23 ± 3) and contented-
ness (25 ± 3, 21 ± 3, 21 ± 3 and 22 ± 3) scores were
calculated. Reactions times (ms) for the four visits were:
479 ± 15, 447 ± 14, 406 ± 17 and 379 ± 18, respectively.
Error rates for the four visits were: 13 ± 2, 15 ± 2, 17 ± 2
and 16 ± 2, respectively.Overall analysis
Electrophysiology
The ipsilateral AUC demonstrated a reduction with
time during the four measurement points in the overall
analysis (F2.0,162.4 = 15.6, P < 0.001). There was a signifi-
cant reduction in ipsilateral AUC attributable to the
variable DRUG (F3,80 = 3.1, P = 0.03). For the contralat-
eral AUC there was a reduction with time (F2.3,175.1 =
9.7, P < 0.001) without a significant DRUG effect for the
overall analysis (F3,80 = 2.6, P = 0.057). There was no
significant effect on the ipsilateral (F3,62 = 2.4, P = 0.064)
or contralateral (F3,47 = 1.1, P = 0.36) latency attribut-
able to DRUG. Latency data were not further analysed.Neuropsychology
From the Bond-Lader scale for the alertness score (F3,80 =
1.02, P = 0.39), the calmness score (F3,80 = 0.79, P = 0.51),
or the contentedness score (F3,80 = 0.36, P = 0.78), there
was no effect of DRUG, although there was a subjective
reduction in alertness over the measurement points
(F1.8,141.3 = 48.1, P < 0.001) not seen with the calmness or
contentedness scores. The reaction time was not affected
across the measurement points (F3,240 = 0.19, P = 0.90) or
by DRUG (F3,80 = 2.1, P = 0.10). The error rates were
constant across time (F3,237 = 1.3 P = 0.28) and not altered
by DRUG (F3,79 = 0.59, P = 0.62).Treatment effects
There was a treatment effect across the study due to
DRUG (F3,60 = 7.3, P < 0.001) in the ipsilateral AUC,
that was further explored. Similarly there was a signifi-
cant overall effect of DRUG on contralateral AUC
(F3,60 = 6.02, P < 0.001).Placebo
The ipsilateral AUC was constant for the placebo infu-
sion at 2011 ± 341, 1907 ± 290, 2056 ± 333 and 1731 ±
258 (μV.ms), respectively, with alpha = 0.96. Similarly
the contralateral AUC was constant at 1336 ± 306, 1305
± 288, 1363 ± 309 and 1187 ± 307, respectively, and again
with alpha = 0.96.
Fig. 2 The effect of the benzodiazepine receptor agonist diazepam on
the nociception specific blink reflex, showing a significant (*, P < 0.05)
reduction in the AUC (μV.ms) ipsilateral to stimulation (Panel a), and no
significant effect contralaterally (b). Measurement periods t1 through t4
reflect the data collection epochs
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The AUCs were 2144 ± 288, 2445 ± 335, 2480 ± 328
and 1955 ± 256 (μV.ms), respectively. Ketamine had
no effect on the ipsilateral AUC when compared with
placebo (P = 0.84). Contralateral AUCs were 1377 ±
245, 1662 ± 304, 1630 ± 289 and 1410 ± 263, respect-
ively. There was no significant effect of ketamine on
contralateral AUC (P = 1.0).
Fentanyl
For fentanyl ipsilateral AUCs were 2340 ± 376, 2219 ±
294, 1852 ± 357 and 1673 ± 334 (μV.ms), respectively.
There was no effect of fentanyl on ipsilateral AUC com-
pared to placebo (P = 1.0). Contralateral AUCs were
1461 ± 324, 1515 ± 359, 1158 ± 295 and 849 ± 218, re-
spectively. There was no significant effect of fentanyl on
contralateral AUC (P = 1.0).
Diazepam
For diazepam ipsilateral AUCs were 1892 ± 299, 1301 ±
284, 756 ± 185 and 580 ± 120 (μV.ms), respectively.
There was a significant decrement in ipsilateral AUC
with diazepam compared to placebo (P = 0.047, Fig. 2).
Contralateral AUCs were 1156 ± 188, 647 ± 161, 328 ± 83
and 284 ± 78. The effect of diazepam did not reach stat-
istical significance for the contralateral AUC (P = 0.07).
Discussion
The study demonstrates an effect of benzodiazepine
receptor modulation on the nociception-specific blink
reflex without a detectable μ-opioid receptor or keta-
mine (glutamate-NMDA receptor) component in this
model. The baseline effects were highly reproducible from
session to session within subjects for four visits, consistent
and extending previous observations [23], demonstrating
the robustness of the method and thus its potential for
serial assessments after suitable intervention.
A study by Kaube and colleagues using the novel con-
centric surface electrode [9] demonstrated an increase of
the R2 component greater than 500 % on the headache
side during acute migraine attacks [32]. An interictal
deficiency in habituation of the nBR in migraine patients
and also in asymptomatic individuals with a family history
of migraine [33] emphasizes the potential for this reflex in
understanding migraine pathophysiology.
Nociception specific blink (nBR) reflex
The nBRr [9] R2 component is increased by more than
500 % in acute migraine [32]. This response seemed
specific to migraine and was not observed in patients
with acute frontal sinusitis [34], or in hypnic headache
[35]. Interestingly, the nBR does not behave differently
from controls in cluster headache in terms of habituation
[36], although there is certainly lateralized facilitation [37].The observation of an interictal persistent change raises
the possibility of an endophenotypic marker for migraine
[33]. This is important when one considers migraine as a
substantially centrally mediated genetic disorder [8]. To
this end triptans, serotonin 5-HT1B/1D receptor agonists
[38], which are highly effective in migraine [39], have also
been reported to affect the nBR. Aspirin and zolmitriptan
suppressed the reflex by 68 and 78 %, respectively, in
migraineurs during an acute attack [40]. Moreover, the A1
receptor agonist GR79236 [41], which is effective in
animal models of trigeminovascular nociception [42] and
in acute migraine [43], also significantly inhibited the nBR.
Taken together the data suggest that the model is help-
ful in understanding likely effects of various agents in
migraine.
nBR human pharmacology
It has been reported that fentanyl, an opioid receptor agon-
ist, and diazepam, which acts by potentiating the GABA
mediated inhibitory effect, both reduce the R2 component
of the blink reflex [18]. Dauthier and colleagues [44] found
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blink reflex. The dose used was slightly higher than the one
employed here. Interestingly, fentanyl at a dose of 100 μg
intramuscularly also failed to affect the R2 component of
the blink reflex [45]. Taken with our studies the data sug-
gest that opioid mechanisms are less important in the
trigeminal system, although the latter studies were con-
ducted with traditional electrodes with their limitations. In
contrast, with the more conventional electrodes, it has been
shown that zolmitriptan reverses blink reflex changes seen
in migraine [46]. It is interesting that ketamine, despite its
use in pain [19] did not alter the nBR. NMDA receptors,
as a therapeutic target for migraine therapy have been
discussed by Nicolodi and Sicutieri [20] who found that
ketamine was effective as acute and preventive migraine
treatment, when compared to placebo. Interestingly,
when used in migraine with hemiplegic or prolonged
aura, ketamine is useful for the aura component but
not for the pain [21, 47].Trigeminocervical nociceptive pharmacology
The new data are broadly consistent with those from
lower species with some caveats [38]. Diazepam modu-
lates the GABAA receptor, and it has been clearly shown
in animals that GABAA mechanisms can modulate noci-
ceptive trigeminovascular transmission at the second
order synapse in the trigeminocervical complex [48]. Simi-
larly, more direct evidence can be seen with studies of the
benzodiazepine receptor in the anaesthetized cat with
midazolam inhibiting transmission at a site where the ef-
fect is reversed by flumazenil [49]. Interestingly, in
humans, the changes induced by diazepam on the R2
component of the blink reflex, were only partially reversed
by flumazenil [18]. There is also a body of evidence from
studies of neurogenically-mediated dural mechanisms for
a role of GABA receptors in this system [50–52]. In con-
trast to the new data, animal studies do suggest the exist-
ence of the mu-opioid receptor in the trigeminocervical
complex [53]. Similarly, there is certainly glutamatergic
transmission at the trigeminocervical complex [54–56]
and again effects in dural models [57, 58], suggesting a
dose or more crucial difference in terms of human trigem-
inal nociceptive transmission.
It might be argued that diazepam’s influence on the
R2 component of the blink reflex is due to a muscle
relaxant effect. However, this was not observed in the
current study with fentanyl. Moreover, previous work
demonstrated a significant reduction of the R2 response
with diazepam doses that did not alter the R1 response
[44, 59]. Since R1 and R2 are mediated by the same
muscle groups, a muscle relaxant effect as an explan-
ation for the R2 response reduction seen after diazepam
administration is not likely.Limitations
The study has some important limitations that need con-
sideration. When studying human volunteers it is impera-
tive to consider safety. Such considerations limit the use of
sedative treatments, particularly opioids whose major sig-
nificant short term side effect is respiratory depression.
Ketamine may have been under-dosed, although the results
are consistent with other published data [47]. Krystal and
colleagues [30] found that doses as low as 0.1 mg/kg caused
psychiatric side effects in healthy volunteers when assessed
by the Brief Psychiatric Rating Scale. Therefore, we chose a
slightly lower dose (0.084 mg/kg), aiming, for both ethical
and scientific purposes, to determine doses with minimal
side effects, which is important since there are a paucity of
human dose ranging studies of ketamine in this use. Keta-
mine is a short acting drug [29] with an effect we would ex-
pect to last no more than minutes and a small therapeutic
window [26]. These pharmacokinetics favor a cumulative
dose regimen as employed here [26], with test batteries per-
formed immediately after or within 10 min after each dose
increase. Our findings are also consistent with data showing
that ketamine at a slightly lower dose than the total used
here was effective as reducing the anxiety without altering
the pain scores [28]. It is important to note the outcome of
the study is limited to the pharmacology of the response
elicited by the nBR, and cannot be generalized to the entire
trigeminal system. Moreover, by using the nBR rather than
a pain scale, we are limited in drawing inferences about
how subjects may rate pain effects with these drugs.Conclusions
We have shown in a carefully conducted three-way
crossover study in volunteers a reduction of the noci-
ception specific blink reflex with the benzodiazepine
receptor agonist diazepam. We have seen no clear
effect of fentanyl, the mu-opioid receptor agonist or
ketamine, the non-competitive glutamate NMDA-
receptor blocker. The study showed a highly reprodu-
cible baseline from week to week within subjects. The
nociception specific blink reflex offers a reproducible,
quantifiable window with which to examine the trigeminal
nociceptive system in humans. Studies of preventive
medicines and putative new anti-migraine treatments
may provide useful insights into both the pathophy-
siology of migraine and help accelerate medicine
development.
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